Blood cancers, Chronic leukaemia, Chronic lymphocytic leukaemia (CLL), Leukaemia
Results
Phase 2
This trial looked at lenalidomide for B cell chronic lymphocytic leukaemia (CLL) that had come back or not responded to treatment.
The trial was open for people to join between 2010 and 2012. The team reported the results in 2016.
Recruitment start: 10 January 2010
Recruitment end: 11 September 2012
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Peter Hillmen
Celgene Corporation
Experimental Cancer Medicine Centre (ECMC)
Last reviewed: 10 September 2018
CRUK internal database number: 5889